PharmaShots Weekly Snapshot (March 30 – April 03, 2020)

1. Sorrento Initiates the Next Phase of its Collaboration with Celularity

Published: Apr 02, 2020 | Tags: Sorrento, Initiates, Next Phase, Collaboration, Celularity

2.  Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic

Published: Apr 03, 2020 | Tags: Celltrion, Enters, Next Phase, Development, Antiviral Therapy, Combat, COVID-19 Pandemic

3.  Novartis and Incyte Intend to Initiate the P-III RUXCOVID Study of Jakavi (ruxolitinib) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

Published: Apr 02, 2020 | Tags: Novartis, Incyte, Intend, Initiate, P-III, RUXCOVID, Study, Jakavi, ruxolitinib, Treatment, Patients, COVID-19, Associated, Cytokine Storm

4. Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19

Published: Apr 02, 2020 | Tags: Amgen, Adaptive Biotechnologies, Collaborate, Develop, Therapies, Targeting, COVID-19

5.  Celularity’s New Cell Therapy Receives the US FDA’s IND Approval for COVID-19

Published: Apr 02, 2020 | Tags: Cellularity, Receives, US, FDA, Approval, IND, New Cell Therapy, COVID-19

6. Pfizer’s Ruxience (biosimilar, rituximab) Receives EC’s Approval for Cancer Indications and Autoimmune Diseases

Published: Apr 02, 2020 | Tags: Pfizer, Ruxience, biosimilar, rituximab, Receives, EC, Approval, Cancer, Autoimmune Diseases

7.  Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Published: Apr 02, 2020 | Tags: Vir, Alnylam, Expand, Existing, Collaboration, Develop, RNAi Therapeutics, Targeting, Host Factors, COVID-19

8. Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Published: Apr 02, 2020 | Tags: Merck, Reports, Results, Keytruda, pembrolizumab, P-III, KEYNOTE-177, Study, Advanced Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

9. Gilead Initiates Two P-III Studies Evaluating Remdesivir (GS-5734) for COVID-19 in the UK

Published: Apr 02, 2020 | Tags: Gilead, Initiates, Two, P-III, Studies, Evaluating, Remdesivir, COVID-19, UK

10. FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments

Published: Apr 01, 2020 | Tags: FDA, Launches, Emergency Program, Expedite, Development, COVID-19, Treatments

11. Y-mAbs Reports the Submission of Naxitamab’s BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma

Published: Apr 01, 2020 | Tags: Y-mAbs, Reports, Submission, Naxitamab, BLA, US, FDA, Relapsed/Refractory, High-Risk Neuroblastoma

12. Three Global Pharmaceutical Companies Launch Worker Volunteer Programs to Combat COVID-19

Published: Apr 01, 2020 | Tags: Three, Global Pharmaceutical Companies, Launch, Worker Volunteer Programs, Combat, COVID-19

13. BD and BioMedomics Launch Rapid Serology Test to Detect Exposure to COVID-19 in 15 Minutes

Published: Mar 31, 2020 | Tags: BD, BioMedomics, Launch, Rapid Serology Test, Detect, Exposure, COVID-19, 15 Minutes

14. QIAGEN’s QIAstat-Dx Test Kit Receives the US FDA’s EUA as the First Syndromic Test to Detect COVID-19

Published:  Mar 31, 2020 | Tags: QIAGEN, QIAstat-Dx Test Kit, Receives, US, FDA, EUA, First Syndromic Test, Detect, COVID-19

15. Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

Published: Mar 31, 2020 | Tags: Daiichi Sankyo, Signs, Non-Exclusive, License Agreement, Ultragenyx, Gene Therapy Manufacturing Technology

16.  Amgen Repurchases Astellas’ Stakes in Amgen Astellas JV to Strengthen its Footprints in Japan

Published: Mar 31, 2020 | Tags: Amgen, Purchases, Shares, Amgen Astellas BioPharma, Strengthen, Presence, Japan

17.  VIVUS Expedites the Launch of Telemedicine and Remote Monitoring Modules for Effective Patient Care During COVID-19

Published: Apr 01, 2020 | Tags: VIVUS, Telemedicine, Remote Monitoring Modules, Effective, Patient Care, During, COVID-19

18. Amgen Provides Update on its Clinical Activities and Medicine Supply Amid COVID-19 Pandemic

Published: Apr 01, 2020 | Tags: Amgen, Provides, Update, Clinical Activities, Medicine Supply, Amid, COVID19 Pandemic

19. Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates

Published: Mar 31, 2020 | Tags: Sorrento, University of Texas Medical Branch, Collaborate, Preclinical Testing, COVID-19, Therapeutic Candidates

20. Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies

Published: Mar 31, 2020 | Tags:  Lilly, Signs, Worldwide, License, Research Agreement, Sitryx, Develop, New Immunometabolic Therapies

21. AstraZeneca’s Lokelma Receives CHMP’s Recommendation for Approval for Patients with Hyperkalemia on Stable Hemodialysis

Published: Mar 31, 2020 | Tags:  AstraZeneca, Lokelma, Receives, CHMP, Recommendation, Approval, Patients, Hyperkalemia, Stable, Hemodialysis

22. The US FDA Authorizes the Emergency Use of Antimalarial Drugs to Combat COVID-19

Published: Mar 30, 2020 | Tags: US, FDA, Authorizes, Emergency Use, Antimalarial Drugs, Combat, COVID-19

23. Bayer’s Nubeqa (darolutamide) Receives the EC’s Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Published: Mar 30, 2020 | Tags: Bayer, Nubeqa, darolutamide, Receives, EC, Approval, Men, Non-Metastatic Castration-Resistant Prostate Cancer

24. Abbott Receives FDA’s Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes

Published: Mar 27, 2020 | Tags: Abbott, Receives, FDA, Emergency Use Authorization, Point-Of-Care Test, Detect, Novel, COVID-19, Five Minutes

25. Johnson & Johnson and BARDA to Fund ~$1B in Research and Development of Novel COVID-19 Vaccines

Published: Mar 30, 2020 | Tags: Johnson & Johnson, BARDA, Fund, ~$1B, Research, Development, Novel, COVID-19 Vaccines

26. BMS’s Zeposia (ozanimod) Receives the CHMP’s Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease

Published: Mar 30, 2020 | Tags: BMS, Zeposia, ozanimod, Receives, CHMP, Positive Opinion, Adults, Relapsing, Remitting, Multiple Sclerosis, Active Disease

27. Eli Lilly’s Taltz (ixekizumab) Receives the US FDA’s Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Published: Mar 30, 2020 | Tags: Eli Lilly, Taltz, ixekizumab, Receives, US, FDA, Approval, Treatment, Pediatric Patients, Moderate to Severe, Plaque Psoriasis

28. AstraZeneca’s Imfinzi (durvalumab) Receives the US FDA’s Approval for Extensive-Stage Small Cell Lung Cancer

Published: Mar 30, 2020 | Tags: AstraZeneca, Imfinzi, durvalumab, Receives, US, FDA, Approval, Extensive-Stage Small Cell Lung Cancer

29. Mylan and Lupin Receive CHMP’s Positive Opinion for Nepexton (biosimilar, etanercept)

Published: Mar 27, 2020 | Tags: Mylan, Lupin, Receive, CHMP, Positive Opinion, Nepexton, biosimilar, etanercept

30. Sanofi and Regeneron Expand Clinical Program of Kevzara (sarilumab) for the Treatment of COVID-19 Outside the US

Published: Mar 30, 2020 | Tags: Sanofi, Regeneron, Expand, Clinical Program, Kevzara, sarilumab, Treatment, COVID-19, Outside the US

31. Sanofi Collaborates with Translate Bio to Develop Novel mRNA Vaccine Against COVID-19

Published: Mar 27, 2020 | Tags: Sanofi, Collaborates, Translate Bio, Develop, Novel, mRNA Vaccine, Against, COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post